Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 209

1.

The efficacy of implantable cardioverter-defibrillators in heart transplant recipients: results from a multicenter registry.

Tsai VW, Cooper J, Garan H, Natale A, Ptaszek LM, Ellinor PT, Hickey K, Downey R, Zei P, Hsia H, Wang P, Hunt S, Haddad F, Al-Ahmad A.

Circ Heart Fail. 2009 May;2(3):197-201. doi: 10.1161/CIRCHEARTFAILURE.108.814525. Epub 2009 Apr 30.

2.

Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.

Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes NA 3rd, Favale S, Piccininno M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P.

JAMA. 2007 Jul 25;298(4):405-12. Erratum in: JAMA. 2007 Oct 3;298(13):1516.

PMID:
17652294
3.

Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis.

Kron J, Sauer W, Schuller J, Bogun F, Crawford T, Sarsam S, Rosenfeld L, Mitiku TY, Cooper JM, Mehta D, Greenspon AJ, Ortman M, Delurgio DB, Valadri R, Narasimhan C, Swapna N, Singh JP, Danik S, Markowitz SM, Almquist AK, Krahn AD, Wolfe LG, Feinstein S, Ellenbogen KA.

Europace. 2013 Mar;15(3):347-54. doi: 10.1093/europace/eus316. Epub 2012 Sep 21.

PMID:
23002195
4.

Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.

Buber J, Luria D, Gurevitz O, Bar-Lev D, Eldar M, Glikson M.

Europace. 2014 Feb;16(2):227-34. doi: 10.1093/europace/eut302. Epub 2013 Oct 9.

PMID:
24108231
5.

Appropriate Implantable Defibrillator Therapy in Adults With Hypertrophic Cardiomyopathy.

Thavikulwat AC, Tomson TT, Knight BP, Bonow RO, Choudhury L.

J Cardiovasc Electrophysiol. 2016 Aug;27(8):953-60. doi: 10.1111/jce.13005. Epub 2016 Jun 1.

PMID:
27138377
6.

Implantable cardioverter defibrillator for primary prevention in patients with severe ventricular dysfunction awaiting heart transplantation.

Cantero-Pérez EM, Sobrino-Márquez JM, Grande-Trillo A, Lage-Gallé E, Rangel-Sousa D, Esteve-Ruiz IM, Martínez-Martínez A.

Transplant Proc. 2013;45(10):3659-61. doi: 10.1016/j.transproceed.2013.10.017.

PMID:
24314988
7.

Use of the implantable cardioverter-defibrillator in long-term survivors of orthotopic heart transplantation.

Ptaszek LM, Wang PJ, Hunt SA, Valantine H, Perlroth M, Al-Ahmad A.

Heart Rhythm. 2005 Sep;2(9):931-3.

PMID:
16171746
8.

Appropriate therapy but not inappropriate shocks predict survival in implantable cardioverter defibrillator patients.

Dichtl W, Wolber T, Paoli U, Brüllmann S, Stühlinger M, Berger T, Spuller K, Strasak A, Pachinger O, Haegeli LM, Duru F, Hintringer F.

Clin Cardiol. 2011 Jul;34(7):433-6. doi: 10.1002/clc.20910. Epub 2011 Jun 15.

9.

Ventricular arrhythmias and sudden cardiac death in adults with congenital heart disease.

Khairy P.

Heart. 2016 Nov 1;102(21):1703-1709. doi: 10.1136/heartjnl-2015-309069. Epub 2016 Jun 1. Review.

PMID:
27250216
10.

Long-term follow-up of implantable cardioverter-defibrillators in adult congenital heart disease patients: indications and outcomes.

Santharam S, Hudsmith L, Thorne S, Clift P, Marshall H, De Bono J.

Europace. 2017 Mar 1;19(3):407-413. doi: 10.1093/europace/euw076.

PMID:
27234868
11.

The ICD for primary prevention in patients with inherited cardiac diseases: indications, use, and outcome: a comparison with secondary prevention.

Olde Nordkamp LR, Wilde AA, Tijssen JG, Knops RE, van Dessel PF, de Groot JR.

Circ Arrhythm Electrophysiol. 2013 Feb;6(1):91-100. doi: 10.1161/CIRCEP.112.975268. Epub 2012 Dec 29.

12.

Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients.

Alsheikh-Ali AA, Link MS, Semsarian C, Shen WK, Estes NA 3rd, Maron MS, Haas TS, Formisano F, Boriani G, Spirito P, Maron BJ.

Heart Rhythm. 2013 Feb;10(2):214-8. doi: 10.1016/j.hrthm.2012.10.003. Epub 2012 Oct 4.

PMID:
23041573
13.

Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.

Roses-Noguer F, Jarman JW, Clague JR, Till J.

Heart Rhythm. 2014 Jan;11(1):58-66. doi: 10.1016/j.hrthm.2013.10.027. Epub 2013 Oct 11.

PMID:
24120999
14.

Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.

Whang W, Mittleman MA, Rich DQ, Wang PJ, Ruskin JN, Tofler GH, Muller JE, Albert CM; TOVA Investigators.

Circulation. 2004 Mar 23;109(11):1386-91. Epub 2004 Mar 1.

15.

Incidence of and predictors for appropriate implantable cardioverter-defibrillator therapy in patients with a secondary preventive implantable cardioverter-defibrillator indication.

Schaer B, Kühne M, Reichlin T, Osswald S, Sticherling C.

Europace. 2016 Feb;18(2):227-31. doi: 10.1093/europace/euv188. Epub 2015 Jun 10.

PMID:
26063686
16.

Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.

Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NA 3rd, Shannon KM, Ashley EA, Day SM, Pacileo G, Formisano F, Devoto E, Anastasakis A, Bos JM, Woo A, Autore C, Pass RH, Boriani G, Garberich RF, Almquist AK, Russell MW, Boni L, Berger S, Maron MS, Link MS.

J Am Coll Cardiol. 2013 Apr 9;61(14):1527-35. doi: 10.1016/j.jacc.2013.01.037.

17.

Effectiveness of subcutaneous implantable cardioverter-defibrillators and determinants of inappropriate shock delivery.

Mesquita J, Cavaco D, Ferreira A, Lopes N, Santos PG, Carvalho MS, Haas A, Costa F, Carmo P, Morgado F, Adragão P, Mendes M.

Int J Cardiol. 2017 Apr 1;232:176-180. doi: 10.1016/j.ijcard.2017.01.034. Epub 2017 Jan 5.

PMID:
28082086
18.

Ventricular arrhythmias in patients with newly diagnosed nonischemic cardiomyopathy: Insights from the PROLONG study.

Duncker D, König T, Hohmann S, Bauersachs J, Veltmann C.

Clin Cardiol. 2017 Aug;40(8):586-590. doi: 10.1002/clc.22706. Epub 2017 Mar 23.

19.

Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death.

Madhavan M, Waks JW, Friedman PA, Kramer DB, Buxton AE, Noseworthy PA, Mehta RA, Hodge DO, Higgins AY, Webster TL, Witt CM, Cha YM, Gersh BJ.

Circ Arrhythm Electrophysiol. 2016 Mar;9(3):e003283. doi: 10.1161/CIRCEP.115.003283.

20.

Dynamic analysis of cardiac rhythms for discriminating atrial fibrillation from lethal ventricular arrhythmias.

DeMazumder D, Lake DE, Cheng A, Moss TJ, Guallar E, Weiss RG, Jones SR, Tomaselli GF, Moorman JR.

Circ Arrhythm Electrophysiol. 2013 Jun;6(3):555-61. doi: 10.1161/CIRCEP.113.000034. Epub 2013 May 16.

Supplemental Content

Support Center